Shots:

• The companies have stopped an ongoing P-III (CUPID STUDY B) trial for not meeting futility criteria that evaluate Dupixent (dupilumab) in 83 patients aged 12 to 80yrs. with CSU who remained symptomatic & were intolerant or incomplete responders to omalizumab
• The therapy did not reach statistical significance in interim analysis despite numeric improvements in itch and hives were observed across key EPs. The safety data were consistent with the known safety profile of Dupixent in its approved indications
• The therapy is also being studied in the P-III trial for EoE & PN and additional results are also expected in 2022 for in pediatric EoE, CindU), and hand and foot AD

 Ref: PR Newswire | Image: Sanofi